Monoclonal antibody 32
Latest Information Update: 14 Aug 1994
At a glance
- Originator Cambridge Antibody Technology; Peptech
- Developer Cambridge Antibody Technology
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Aug 1994 Discontinued-Preclinical for Cancer in United Kingdom (Unknown route)